Soleno Priority Review of NDA in Prader-Willi Syndrome

 PDUFA target action date set for December 27, 2024

FDA currently plans to hold an Advisory Committee meeting

https://www.globenewswire.com/news-release/2024/08/27/2936152/0/en/Soleno-Therapeutics-Announces-U-S-FDA-Acceptance-for-Filing-and-Priority-Review-of-NDA-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome.html